Directly following the cell therapy panel discussion in part 1, Precision experts Phil Cyr, Deb Phippard and David Parker, and Project Pharma’s Tony Khoury joined C-Suite leaders from advanced therapy companies for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 2- Gene Therapy.

Miss ASGCT 2021? Check out this cell therapy panel discussion you won’t want to miss! Precision experts David Parker, Alex Grosvenor and Megan Liles, and Project Farma’s John Khoury join biotech executives on the front lines of development for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 1 – Cell Therapy.

Co-hosted by Endpoints Webinars, this panel discussion will address the growing industry concerns regarding manufacturing hurdles unique to cell and gene therapy.  Watch as our panel of experts helps set the landscape for the current state of the advanced therapy sector and share key considerations that go into deciding whether to scale-up manufacturing internally or look to an external supplier like a CDMO.

Delivering a gene therapy to market requires a comprehensive and integrated approach. At the 4th annual Gene Therapy for Rare Disorders Conference, Precision ADVANCE participated in a panel discussion, and Precision for Medicine held two clinical presentations, providing crucial insights for clinical development, manufacturing, and commercialization of gene therapies.